Literature DB >> 19579225

A statistical model for the dependence between progression-free survival and overall survival.

Frank Fleischer1, Birgit Gaschler-Markefski, Erich Bluhmki.   

Abstract

Among the surrogate endpoints for overall survival (OS) in oncology trials, progression-free survival (PFS) is more and more taking the leading role. Although there have been some empirical investigations on the dependence structure between OS and PFS (in particular between the median OS and the median PFS), statistical models are almost non-existing. This paper aims at filling this gap by introducing an easy-to-handle model based on exponential time-to-event distributions that describe the dependence structure between OS and PFS. Based on this model, explicit formulae for individual correlations are derived together with a lower bound for the correlation of OS and PFS, which is given by the fraction of the two medians for OS and PFS. Two methods on how to estimate the parameter of the model from real data are discussed. One method is based on a maximum-likelihood estimator whereas the other method uses a plug-in approach. Three examples from non-small cell lung cancer are considered. In the first example, the parameters of the model are determined and the estimated survival curce is compared with the observed one. The second example explains how to obtain sample size estimates for OS based on assumptions on median PFS and OS. Finally, the third example provides a way of modelling and quantifying confounding effects that might explain a levelling of differences in OS although a difference in PFS is observed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19579225     DOI: 10.1002/sim.3637

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  20 in total

1.  Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy.

Authors:  Daniel Y C Heng; Wanling Xie; Georg A Bjarnason; Ulka Vaishampayan; Min-Han Tan; Jennifer Knox; Frede Donskov; Lori Wood; Christian Kollmannsberger; Brian I Rini; Toni K Choueiri
Journal:  Cancer       Date:  2010-11-18       Impact factor: 6.860

2.  A Multi-state Model for Designing Clinical Trials for Testing Overall Survival Allowing for Crossover after Progression.

Authors:  Fang Xia; Stephen L George; Xiaofei Wang
Journal:  Stat Biopharm Res       Date:  2016-03-22       Impact factor: 1.452

3.  A Weibull multi-state model for the dependence of progression-free survival and overall survival.

Authors:  Yimei Li; Qiang Zhang
Journal:  Stat Med       Date:  2015-04-10       Impact factor: 2.373

4.  Estimation of time to progression and post progression survival using joint modeling of summary level OS and PFS data with an ordinary differential equation model.

Authors:  Mario Nagase; Sameer Doshi; Sandeep Dutta; Chih-Wei Lin
Journal:  J Pharmacokinet Pharmacodyn       Date:  2022-07-23       Impact factor: 2.410

5.  Individual-level data on the relationships of progression-free survival and post-progression survival with overall survival in patients with advanced non-squamous non-small cell lung cancer patients who received second-line chemotherapy.

Authors:  Hisao Imai; Keita Mori; Akira Ono; Hiroaki Akamatsu; Tetsuhiko Taira; Hirotsugu Kenmotsu; Tateaki Naito; Kyoichi Kaira; Haruyasu Murakami; Masahiro Endo; Takashi Nakajima; Toshiaki Takahashi
Journal:  Med Oncol       Date:  2014-06-25       Impact factor: 3.064

6.  Surrogate endpoints for overall survival in advanced non-small-cell lung cancer patients with mutations of the epidermal growth factor receptor gene.

Authors:  Reiko Yoshino; Hisao Imai; Keita Mori; Kousuke Takei; Mai Tomizawa; Kyoichi Kaira; Akihiro Yoshii; Yoshio Tomizawa; Ryusei Saito; Masanobu Yamada
Journal:  Mol Clin Oncol       Date:  2014-07-01

7.  Sample size determination for clinical trials with co-primary outcomes: exponential event times.

Authors:  Toshimitsu Hamasaki; Tomoyuki Sugimoto; Scott Evans; Takashi Sozu
Journal:  Pharm Stat       Date:  2012-10-19       Impact factor: 1.894

8.  Progression-free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancer.

Authors:  Hisao Imai; Keita Mori; Kazushige Wakuda; Akira Ono; Hiroaki Akamatsu; Takehito Shukuya; Tetsuhiko Taira; Hirotsugu Kenmotsu; Tateaki Naito; Kyoichi Kaira; Haruyasu Murakami; Masahiro Endo; Takashi Nakajima; Nobuyuki Yamamoto; Toshiaki Takahashi
Journal:  Ann Thorac Med       Date:  2015 Jan-Mar       Impact factor: 2.219

9.  Post-Progression Survival Is Strongly Associated with Overall Survival in Patients Exhibiting Postoperative Relapse of Non-Small-Cell Lung Cancer Harboring Sensitizing EGFR Mutations.

Authors:  Hisao Imai; Ryoichi Onozato; Maiko Ginnan; Daijiro Kobayashi; Kyoichi Kaira; Koichi Minato
Journal:  Medicina (Kaunas)       Date:  2021-05-19       Impact factor: 2.430

10.  Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology.

Authors:  Beth Sherrill; James A Kaye; Rickard Sandin; Joseph C Cappelleri; Connie Chen
Journal:  Onco Targets Ther       Date:  2012-10-23       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.